Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingDenali Therapeutics Inc. ("Denali" or the “Company”) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases and lysosomal storage diseases. The Company is headquartered in South San Francisco, California. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2023 · $294.1MThe company’s own SEC segment disclosure.
- ATV Abeta Program License$293.9M100%
- Option Services$211.0K0%
Denali Therapeutics Inc. (DNLI) reported revenue of $3.6M in Q2 2026 (quarter ended Jun 30, 2026). That came with a gross margin of 97% and net loss of $128M. For the full year FY2025, revenue was $0 and net income −$513M. Its largest product in Q2 2023 (quarter ended Jun 30, 2023) was ATV Abeta Program License at $294M, 100% of the disclosed total, well ahead of Option Services at 0.1%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.